| Novartis Q2 net up 14% at Rs 33 cr | 29-OCT-09 |
|
| Novartis India today reported a 13.94 per cent jump in its net profit at Rs 33.3 crore for the second quarter of the current financial year. |
|
|
|
| Vitamins boost pharma growth | 26-OCT-09 |
|
| Vitamins and minerals are among the drug therapeutic groups showing the fastest growth in sales in the domestic pharmaceutical market over the past year, show data from the research company ORG-IMS. |
|
|
|
| Latha Jishnu: The campaign against that pesky 3 (d) | 14-OCT-09 |
|
| For the Americans (and some Europeans) it’s “that pesky section”. And the US government is throwing its weight behind an industry campaign to discredit this section if not get it removed from India’s Patent Act. Yes, of course, it is Section 3(d) that is under attack from big pharma which has lost no opportunity in pointing out that this law will stifle the growth of India’s own drug companies and also choke off foreign investment in the sector. In recent weeks, this campaign has picked up in tempo both here and abroad. |
|
|
|
|
|
|
| Brazil, India to oppose EU at WTO | 22-SEP-09 |
|
| Brazil would join India in invoking dispute settlement proceedings against the European Union at the World Trade Organization (WTO) over Brussels’ alleged violation of global trade rules by detaining on the high seas the generic drugs exported by Indian companies to other developing countries, a senior Indian trade official has said. |
|
|
|
| H1N1 drug trial talks next week | 18-SEP-09 |
|
| Multinational drug firms Novartis, GlaxoSmithKline and Baxter are likely to initiate discussions with the Union health ministry next week on conducting clinical trials for H1N1 (swine flu) medicine. |
|
|
|
|
|
|
| SC issues notices to Centre, others on Novartis petition | 11-SEP-09 |
|
| The Supreme Court today issued notices to the Centre, pharma major Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on a pettion filed by Swiss firm Novartis AG challenging the denial of patent for its blood cancer drug Glivec in beta crystal form. |
|
|
|
| Novartis India to quadruple its business in 5 years | 09-SEP-09 |
|
| Novartis India, a subsidiary of Switzerland-based Novartis AG, is all set to grow its business revenues by four times in the next five years. The company's over-the-counter business unit is looking at introducing more products in the consumer healthcare segment. |
|
|
|
| Novartis: Puppy power | 08-SEP-09 |
|
| The puppy has come to life. Calcium Sandoz, the 40-year-old calcium supplement brand for kids from Novartis, has long been synonymous with its cute ‘puppy’ packs. The company has now rolled out a television commercial which for the first time features the puppy in action — it helps a kid do his everyday tasks and activities with ease. |
|
|
|
|
|
|
|
|
|
| SC to hear Novartis case next week | 31-AUG-09 |
|
| The Supreme Court will hear Swiss drug maker Novartis AG's plea against denial of patent for its blood cancer drug, Glivec, next week. |
|
|
|
| Novartis moves SC against Glivec order | 29-AUG-09 |
|
| Swiss drug major Novartis has approached the Supreme Court against a decision of the country’s apex patent complaint redressal forum, the Intellectual Property Appellate Board (IPAB), to deny patent protection for its cancer medicine, Glivec. |
|
|
|
| Novartis gains on hopes of flu vaccine order | 12-AUG-09 |
|
| Novartis India surged over 4% to Rs 447. The scrip touched a high of Rs 450 and a low of Rs 434 during the day. The counter witnessed a volume 13,914 shares, which is more than two-fold increase in its two-week average traded quantity of 5,919 shares. |
|
|
|
Content Guide
